News | November 09, 2021
Wockhardt PAT at Rs 33.53 cr. in Q2FY22
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
It is the world’s first DNA-based Covid vaccine
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The solution helps the pharma enterprises drive efficiencies, save costs, and increase productivity
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Subscribe To Our Newsletter & Stay Updated
